Home>About Activase (t-PA) for Stroke In acute ischemic stroke, prepare yourself with the capability to Reverse neurologic impairment* Why choose to reperfuse? Activase (t-PA) can reverse neurologic impairment* through a targeted mechanism of action (MOA) View video More stroke patients recover with minimal or no disability at 3 months and 1 year3,4 Numerous studies support the safety of Activase (t-PA)5-27 Over a decade of real-world experience in >100,000 patients28,29 Activase (t-PA) is part of stroke management guidelines or statements by: American Heart Association / American Stroke Association Brain Attack Coalition American Academy of Neurology American College of Emergency Physicians Genentech is neither affiliated with nor endorses any of these organizations. * Defined by the National Institutes of Health (NIH) Stroke Scale score compared to baseline.

Indication: Activase is indicated for the management of acute ischemic stroke in adults for improving neurological recovery and reducing the incidence of disability. Treatment should only be initiated within 3 hours after the onset of stroke symptoms, and after exclusion of intracranial hemorrhage by a cranial computerized tomography (CT) scan or other diagnostic imaging method sensitive for the presence of hemorrhage (see CONTRAINDICATIONS in the full prescribing information).

Safety Information: All thrombolytic agents increase the risk of bleeding, including intracranial bleeding, and should be used only in appropriate patients. Not all patients with acute ischemic stroke will be eligible for Activase therapy, including patients with evidence of recent or active bleeding; recent (within 3 months) intracranial or intraspinal surgery, serious head trauma, or previous stroke; uncontrolled high blood pressure; or impaired blood clotting.